Governments, Law Enforcement, and Industry Leaders to Convene at Global Anti-Scam Summit Americas 2024 in Washington D.C.
Global Anti-Scam Alliance hosts strategy workshops designed to develop better protections for consumers against scams
WASHINGTON, DC / ACCESSWIRE / October 24, 2024 / Online scams wreak havoc across the Americas and globally, causing significant financial and emotional damage. The Global Anti-Scam Summit (GASS) Americas 2024, organized by the Global Anti-Scam Alliance (GASA) and hosted by Amazon.com, Inc., aims to combat these growing threats. The summit will feature over 30 hours of presentations, workshops, and interactive sessions across ten critical tracks, all focused on developing a global defense strategy to protect consumers and inform regulation.
The summit will empower experts to take decisive action by focusing on the impact on victims, highlighting global scam statistics, explaining emerging scam tactics, and fostering international cooperation. The aim is to provide a roadmap for regulatory bodies to drive meaningful change.
With $1.026 billion in global scam losses in 2023, this event seeks to mitigate further damage in 2024 and beyond.
Day 1 will address the human and policy aspects of scams:
Victim Impact: Led by AARP, this session delves into the emotional and financial toll on victims and their communities.
Policy: The Aspen Institute will explore regulatory gaps and legislative solutions, sharing best practices from around the world.
Law Enforcement: Chaired by UNODC, this session focuses on the collaboration between local and international agencies to disrupt scam networks.
Data & Signal Sharing: GASA and DNS Research Federation will unveil plans for an international cybercrime exchange to reduce cybercrime by 50% in 10 years.
Bank Collaboration: This session, led by Feedzai, will explore the critical role of banks in preventing scams.
Day 2 will shift to specific industries and technologies most at risk:
Financial Services: Featuring industry leaders like Capital One and Mastercard, this session will explore how multi-sector collaboration can build the perfect anti-fraud infrastructure.
Telecom: Focuses on how telecom companies can improve security to protect consumers.
Customer Digital Experience: Major platforms like Amazon will discuss how to strengthen protections at key digital touchpoints.
Blockchain: Investigating scams in crypto and blockchain, chaired by Cube3.AI.
Cybersecurity: Trend Micro will lead panels on advanced investigation techniques, focusing on scams like sextortion and pig butchering.
Uniting Expertise for a Scam-Free Future
"Consumers globally are facing a crisis with scams. Governments, private industry, and law enforcement must come together and act now," says Jorij Abraham, Managing Director of GASA. "Our aim at this summit is not only to discuss the problems but to build solutions that protect consumers worldwide."
Confirmed Speakers:
Glen Prichard, UNODC
Jean-Jacques Sahel, Google
Matthew Noyes, U.S. Secret Service
Laura Quevedo, Mastercard
Ben Chance, Zelle
Amy Nofziger, AARP
Mauro Ellovitch, MPMG
The summit will also launch the annual Global State of Scams Report 2024, offering an in-depth analysis of major scam trends and their impact.
Join us in Washington, D.C., for this landmark event. Visit gasa.org/gass-2024-americas to view the full schedule and register.
Contact Information
Sam Rogers
Marketing Director, Global Anti-Scam Alliance
sam.rogers@gasa.org
SOURCE: Global Anti-Scam Alliance (GASA)
View the original press release on newswire.com.
Global Anti-Scam Alliance
Subscribe to releases from Accesswire
Subscribe to all the latest releases from Accesswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Accesswire
VisiRose Introduces Revolutionary Therapy for Severe Eye Infections10.12.2024 07:30:00 CET | Press Release
Collaboration between Bascom Palmer Eye Institute and Provectus Biopharmaceuticals KNOXVILLE, TN / ACCESSWIRE / December 10, 2024 / VisiRose, a clinical-stage biotechnology company, is introducing Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT), a groundbreaking, non-invasive investigational treatment for infectious keratitis and other serious eye infections developed by the University of Miami Miller School of Medicine's Bascom Palmer Eye Institute (BPEI). VisiRose, a newly launched company of Provectus Biopharmaceuticals (OTCQB:PVCT) and the University, is focused on commercializing this innovative ocular research by combining a formulation of Provectus's pharmaceutical-grade bioactive synthetic small molecule Rose Bengal Sodium (RBS) and BPEI's light-based medical device to treat eye infections caused by bacteria, fungi, and parasites. RB PDAT offers a potential solution to the growing global problem of antimicrobial resistance (AMR), providing a broad-spectrum ocular thera
Young Girl Discovers a 3,500-year-old Egyptian Amulet9.12.2024 07:40:00 CET | Press Release
During a family trip near an archaeological site in Hod Hasharon, 12-year-old Dafna Filshteiner found an ancient scarab. LONDON, UK / ACCESSWIRE / December 9, 2024 / Dafna Filshteiner, age 12, was recently hiking below the ancient site of Tel Qana in Hod Hasharon, when suddenly, to her surprise, she discovered an unusual find a beetle-like stone used as an Egyptian amulet about 3,500 years ago. "I was looking down at the ground to find porcupine needles and smooth pebbles," she says. "And suddenly I picked up an interesting stone. I showed it to my mother, and she said it was just an ordinary stone or a bead. But then I saw a decoration and stubbornly insisted it was more than that, so we searched on the Internet. There, we identified more photos of stones similar to what we had found. We realized that it was something special and immediately called the Antiquities Authority." The family turned to Mor Wiesel, an archaeologist at the Israel Antiquities Authority, who thanked Dafna and h
Loar Announces Launch of Public Offering9.12.2024 06:30:00 CET | Press Release
WHITE PLAINS, NY / ACCESSWIRE / December 9, 2024 / Loar Holdings Inc. (NYSE:LOAR) ("Loar") announced today that it has launched the roadshow for the public offering of 4,750,000 shares of its common stock, including 1,583,333 shares offered by certain stockholders and 3,166,667 shares offered by Loar. In addition, such selling stockholders expect to grant the underwriters a 30-day option to purchase up to 712,500 additional shares of common stock at the public offering price, less underwriting discounts and commissions. Loar intends to use the net proceeds from this offering for repayment of borrowings outstanding under its credit agreement and, to the extent of any remaining proceeds, for general corporate purposes, including working capital. Loar will not receive any of the proceeds from the sale of common stock offered by the selling stockholders, including any common stock sold pursuant to any exercise by the underwriters of their option to purchase additional shares. Jefferies and
ProteinQure to Present Data on PQ203, a Novel Peptide-Drug Conjugate for Triple Negative Breast Cancer, at 2024 San Antonio Breast Cancer Symposium6.12.2024 12:30:00 CET | Press Release
TORONTO, ON / ACCESSWIRE / December 6, 2024 / ProteinQure, the leading company in computational design of peptide therapeutics, will be presenting compelling new data on the progress of their lead triple negative breast cancer (TNBC) drug PQ203 (December 12, 2024 presentation ID: P4-12-17) at the 2024 San Antonio Breast Cancer Symposium. PQ203 is a novel Peptide Drug Conjugate composed of a Sortilin receptor targeting peptide conjugated to the cytotoxic agent monomethyl auristatin E. The Sortiin receptor is expressed in a high percentage of diseased tissue from TNBC patients and as such represents an innovative treatment for this challenging sub-type of breast cancer. ProteinQure has recently generated data that PQ203 exhibits potent efficacy in a patient-derived xenograft (PDX) model resistant to Sacituzumab Govitecan (Trodelvy™), an antibody drug conjugate that is the emerging standard of care for metastatic TNBC. Additionally, PQ203 has shown an encouraging safety profile. Based on
CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 20245.12.2024 09:10:00 CET | Press Release
Live webcast discussion featuring internationally renowned Glioblastoma Multiforme (GBM) Key Opinion Leaders Company committed to addressing the most aggressive type of brain cancer with an average survival of only 14 to 16 months after diagnosis and no cure Register for the event here HOUSTON, TX / ACCESSWIRE / December 5, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it will host a Virtual Analyst & Investor Day on Wednesday, December 11th from 11:30 AM - 1:00 PM ET. For the event, John Climaco, Chief Executive Officer, Sandra Silberman, MD, PhD, Chief Medical Officer and Zena Muzyczenko, Vice President of Clinical Operations at CNS Pharmaceuticals will be joined by Key Opinion Leaders: Michael Weller, Prof. Dr. med. Director of Department, Department of Neurology, Universitatsspital, Zur
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom